We mined CB Insights business relationship data on Pfizer to highlight who it’s working with and distill its areas of strategic focus.
More than investing in or acquiring companies, Pfizer actively partners with companies. Yet partnerships — ranging from licensing to its vendors to co-creation of products — is not an area deeply understood or analyzed. This is mostly because this data has not traditionally been easily accessible.
For the last 4 years, we’ve been amassing the world’s largest business relationship database to make this data accessible and available to our customers. Today, we’ll dig into Pfizer’s 2023 partnerships and highlight what it reveals about its strategy. Customers can access the underlying table of all Pfizer’s partnerships here or under the “network” tab on Pfizer’s company profile.
In this brief, we’ll break down:
- What types of partnerships is Pfizer striking?
- What do these partnerships reveal about Pfizer’s strategy?
- A breakdown and graphic timeline of Pfizer’s 2023 partnerships
What types of partnerships is Pfizer striking?
As we look at Pfizer’s 2023 partnerships, we see them falling into 3 main buckets:
- Collaborative research and development (42%): This includes partnerships where Pfizer is working with academic institutions, research organizations, and biotech companies to develop new therapies and treatments for various diseases.
- Access and distribution (42%): This includes partnerships aimed at expanding access to Pfizer’s vaccines, therapies, treatments, and related information as well as improving production and distribution globally.
- Manufacturing (17%): This includes partnerships aimed at expanding Pfizer’s manufacturing capacity to bring new treatments to market.
What do these partnerships reveal about Pfizer’s strategy?
Some strategic areas of focus become apparent as we analyze Pfizer’s 2023 partnerships:
- Focused on many geographies, especially Asia: Pfizer’s partnerships span various regions, including North America, Europe, and Asia. Several partnerships are focused on improving the development, production, and distribution of treatments and therapies in Asia, specifically.
- Covid-19 remains a disease focus among others: Pfizer’s partnerships cover a diverse range of therapeutic areas, including Covid-19, oncology, rare diseases, and fibrotic diseases.
- Technology for drug discovery and development is top of mind: Several partnerships involve the use of innovative technologies such as artificial intelligence and gene editing to accelerate drug discovery and development with a focus on oncology.
